Given the crucial roles of GSK-3β in epithelial–mesenchymal transition (EMT), we assume that it may also be involved in tumor stemness, immune evasion, and drug resistance in triple-negative breast cancer (TNBC). This evidence concerns the gene GSK3B and triple-negative breast carcinoma.